Literature DB >> 3548616

Effect of preoperative antiplatelet drugs on vascular prostacyclin synthesis.

S V Karwande, B B Weksler, W A Gay, V A Subramanian.   

Abstract

Patients undergoing aortocoronary bypass using autogenous saphenous veins were randomly divided into three comparable groups. Group 1 (n = 10) acted as a control, Group 2 (n = 14) received 80 mg of aspirin at midnight before the operation, and Group 3 (n = 12) received 80 mg of aspirin and 75 mg of dipyridamole at midnight and an additional 75-mg dose of dipyridamole at 6 AM. The purpose was to determine which regimen would maximally inhibit platelet function without depressing vascular prostacyclin synthesis. Serum thromboxane A2, saphenous vein wall and aortic wall prostacyclin, platelet aggregation, and bleeding time were measured in all patients. None was restarted on a regimen of aspirin or dipyridamole postoperatively. Aspirin alone and in combination with dipyridamole significantly inhibited thromboxane A2 and platelet aggregation in all treated patients but spared venous prostacyclin synthesis. Aortic prostacyclin synthesis was partially inhibited in both treated groups. Chest tube drainage was comparable in all three groups. These results indicate that the combination of aspirin and dipyridamole offers no measurable advantage over aspirin alone in the perioperative period.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548616     DOI: 10.1016/s0003-4975(10)60623-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

Review 1.  Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review.

Authors:  Ayman Elbadawi; Marwan Saad; Ramez Nairooz
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

2.  Aspirin and postoperative bleeding after coronary artery bypass grafting.

Authors:  Victor A Ferraris; Suellen P Ferraris; Oji Joseph; Paulette Wehner; Robert M Mentzer
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.